362 related articles for article (PubMed ID: 25827941)
1. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study.
Francis CW; Kessler CM; Goldhaber SZ; Kovacs MJ; Monreal M; Huisman MV; Bergqvist D; Turpie AG; Ortel TL; Spyropoulos AC; Pabinger I; Kakkar AK
J Thromb Haemost; 2015 Jun; 13(6):1028-35. PubMed ID: 25827941
[TBL] [Abstract][Full Text] [Related]
2. Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study.
Di Nisio M; van Es N; Carrier M; Wang TF; Garcia D; Segers A; Weitz J; Buller H; Raskob G
J Thromb Haemost; 2019 Nov; 17(11):1866-1874. PubMed ID: 31271705
[TBL] [Abstract][Full Text] [Related]
3. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
McBane Ii R; Loprinzi CL; Ashrani A; Perez-Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Le-Rademacher JG; Wysokinski WE
Thromb Haemost; 2017 Oct; 117(10):1952-1961. PubMed ID: 28837207
[TBL] [Abstract][Full Text] [Related]
4. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
Kraaijpoel N; Di Nisio M; Mulder FI; van Es N; Beyer-Westendorf J; Carrier M; Garcia D; Grosso M; Kakkar AK; Mercuri MF; Middeldorp S; Hernandez CR; Santamaria A; Schwocho L; Segers A; Verhamme P; Wang TF; Weitz JI; Zhang G; Zwicker JI; Büller HR; Raskob GE
Thromb Haemost; 2018 Aug; 118(8):1439-1449. PubMed ID: 30060256
[TBL] [Abstract][Full Text] [Related]
5. Multicenter dose-finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism.
O'Brien SH; Kulkarni R; Wallace A; Hamblin F; Burr S; Goldenberg NA
J Thromb Haemost; 2014 Nov; 12(11):1822-5. PubMed ID: 25182454
[TBL] [Abstract][Full Text] [Related]
6. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
Agnelli G; Becattini C; Meyer G; Muñoz A; Huisman MV; Connors JM; Cohen A; Bauersachs R; Brenner B; Torbicki A; Sueiro MR; Lambert C; Gussoni G; Campanini M; Fontanella A; Vescovo G; Verso M;
N Engl J Med; 2020 Apr; 382(17):1599-1607. PubMed ID: 32223112
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of cancer-associated venous thromboembolism].
Di Nisio M
G Ital Cardiol (Rome); 2018 Sep; 19(9 Suppl 1):7S-12S. PubMed ID: 30284557
[TBL] [Abstract][Full Text] [Related]
8. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis.
Giustozzi M; Agnelli G; Del Toro-Cervera J; Klok FA; Rosovsky RP; Martin AC; Herold J; Tzoran I; Szmit S; Bertoletti L; Becattini C; Huisman MV
Thromb Haemost; 2020 Jul; 120(7):1128-1136. PubMed ID: 32365386
[TBL] [Abstract][Full Text] [Related]
9. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
[TBL] [Abstract][Full Text] [Related]
10. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).
Young AM; Marshall A; Thirlwall J; Chapman O; Lokare A; Hill C; Hale D; Dunn JA; Lyman GH; Hutchinson C; MacCallum P; Kakkar A; Hobbs FDR; Petrou S; Dale J; Poole CJ; Maraveyas A; Levine M
J Clin Oncol; 2018 Jul; 36(20):2017-2023. PubMed ID: 29746227
[TBL] [Abstract][Full Text] [Related]
11. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
Raskob GE; van Es N; Verhamme P; Carrier M; Di Nisio M; Garcia D; Grosso MA; Kakkar AK; Kovacs MJ; Mercuri MF; Meyer G; Segers A; Shi M; Wang TF; Yeo E; Zhang G; Zwicker JI; Weitz JI; Büller HR;
N Engl J Med; 2018 Feb; 378(7):615-624. PubMed ID: 29231094
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
Robertson L; Strachan J
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
[TBL] [Abstract][Full Text] [Related]
13. Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial.
Planquette B; Bertoletti L; Charles-Nelson A; Laporte S; Grange C; Mahé I; Pernod G; Elias A; Couturaud F; Falvo N; Sevestre MA; Ray V; Burnod A; Brebion N; Roy PM; Timar-David M; Aquilanti S; Constans J; Bura-Rivière A; Brisot D; Chatellier G; Sanchez O; Meyer G; Girard P; Mismetti P;
Chest; 2022 Mar; 161(3):781-790. PubMed ID: 34627853
[TBL] [Abstract][Full Text] [Related]
14. Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism.
Verso M; Munoz A; Bauersachs R; Huisman MV; Mandalà M; Vescovo G; Becattini C; Agnelli G
Eur J Cancer; 2021 May; 148():371-381. PubMed ID: 33780665
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study.
Giustozzi M; Connors JM; Ruperez Blanco AB; Szmit S; Falvo N; Cohen AT; Huisman M; Bauersachs R; Dentali F; Becattini C; Agnelli G
J Thromb Haemost; 2021 Nov; 19(11):2751-2759. PubMed ID: 34260816
[TBL] [Abstract][Full Text] [Related]
16. Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis.
Schulman S; Zondag M; Linkins L; Pasca S; Cheung YW; de Sancho M; Gallus A; Lecumberri R; Molnar S; Ageno W; Le Gal G; Falanga A; Hulegårdh E; Ranta S; Kamphuisen P; Debourdeau P; Rigamonti V; Ortel TL; Lee A
J Thromb Haemost; 2015 Jun; 13(6):1010-8. PubMed ID: 25851122
[TBL] [Abstract][Full Text] [Related]
17. Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients.
Droege ME; Mueller EW; Besl KM; Lemmink JA; Kramer EA; Athota KP; Droege CA; Ernst NE; Keegan SP; Lutomski DM; Hanseman DJ; Robinson BR
J Trauma Acute Care Surg; 2014 Feb; 76(2):450-6. PubMed ID: 24458050
[TBL] [Abstract][Full Text] [Related]
18. Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial.
Yhim HY; Choi WI; Kim SH; Nam SH; Kim KH; Mun YC; Oh D; Hwang HG; Lee KW; Song EK; Kwon YS; Bang SM
Korean J Intern Med; 2019 Sep; 34(5):1125-1135. PubMed ID: 29788694
[TBL] [Abstract][Full Text] [Related]
19. Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study.
Woodruff S; Lee AYY; Carrier M; Feugère G; Abreu P; Heissler J
J Thromb Thrombolysis; 2019 May; 47(4):495-504. PubMed ID: 30859370
[TBL] [Abstract][Full Text] [Related]
20. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M;
N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
